Treatment Considerations and Sequencing in Multiple Myeloma


The expert panel concludes their discussion with clinical insights on treatment sequencing and therapeutic decision-making for patients who have relapsed.

This is a video synopsis/summary of a Peer Exchange featuring Krina K. Patel, MD, MSc; Amrita Krishnan, MD; Caitlin Costello, MD; Saad Z. Usmani, MD, MBA, FACP; and Rafat Abonour, MD.

The discussion focuses on sequencing B-cell maturation antigen (BCMA)–targeted therapies. Continuing one BCMA bispecific antibody after progression on another may have limited efficacy due to outgrowth of BCMA loss mutations and T-cell exhaustion. A period of non-BCMA–directed therapy could help restore T-cell fitness before switching targets, like to GPRC5D with cibisatamab or teclistamab. More clinical and biologic tools are still needed to better understand resistance mechanisms among bispecific antibodies, antibody-drug conjugates, and CAR T-cell therapy to inform sequencing.

Off-the-shelf allogeneic CAR T-cell therapy could facilitate faster retreatment compared to autologous manufacturing. Continued research into optimal sequencing strategies is still needed and will be better informed by longer follow-up of currently available BCMA therapies.

Video synopsis is AI-generated and reviewed by OncLive® editorial staff.

Related Videos
Francesco Di Meo, PhD
A panel of 5 experts on renal cell carcinoma
Chandler H. Park, MD, an expert on renal cell carcinoma
Video 8 - "Post-Thyroidectomy Management: Thyroid Hormone Replacement and TSH Suppression"
Video 7 - "The Importance of Thyroidectomy in DTC Patient Care"
Shannon N. Westin, MD, MPH, FACOG, director, Early Drug Development, clinical medical director, professor, Department of Gynecologic Oncology and Reproductive Medicine, Division of Surgery, codirector, Ovarian Cancer Moonshot Program, The University of Texas MD Anderson Cancer Center
Hans Lee, MD, associate professor, director, Multiple Myeloma Clinical Research, Department of Lymphoma/Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
Michael J. Overman, MD
A panel of 6 experts on colorectal cancer
A panel of 6 experts on colorectal cancer